Capital Pro-Egaux Inc (NEX: CPE.H) Announces the Conclusion of a Settlement Agreement with 3shape A/S

MORIN-HEIGHTS, QC / ACCESSWIRE / April 17, 2015 / Capital Pro-Egaux Inc. (the "Company") (NEX:CPE-H.V - News) announces that its wholly-owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a Settlement and Patent License Agreement with 3Shape A/S. As part of the agreement, Sinlab granted 3Shape and its affiliates a license in and to all of its digital dentistry patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons. The license for the Technobar technology extends to 3Shape and certain non-manufacturing resellers of 3Shape digital dentistry software. The license for Technoguide technologies extends to 3Shape only. End user, manufacturing reseller, and Technoguide technology licenses can be made available to those not covered by the license. Unlicensed entities should obtain an appropriate license from Sinlab by contacting M. Jean Kingsley at jeanjkingsley@outlook.com or by contacting 3Shape.

The Company previously announced settlement and/or license agreements that include Biomet 3i, LLC (formerly Implant Innovations, Inc.); Delcam USA, Inc. and Delcam Holdings, Inc.; Cagenix, Inc.; Dentsply International Inc.; Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Medical Inc.; Nobel Biocare USA, LLC; and Nobel Biocare Procera, LLC. The Company is currently pursuing its licensing program with other industry participants. The Company cannot predict the outcome of its ongoing negotiations or of any legal proceedings it may decide to institute against those entities that fail or refuse to contract a license. The decision to take legal proceedings will be based on available information and the Company's assessment of all relevant facts and circumstances, including costs involved with such proceedings. Such costs are unpredictable and may be substantial.

The Company also announces that European Patent Office (EPO) communicated its written report detailing the decision of maintaining certain Sinlab patents as granted over the opposition pursued by Sicat in 2010. The Company announced the verbal decision on January 30, 2015.

Caution regarding forward-looking statements

This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and the institution of legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.

About Pro-Egaux Inc.

Pro-Egaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.

Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information about this Press Release:

Capital Pro-Egaux Inc.
Pierre Desormeau
President
Tel.: (514) 616-0612
Fax: (450) 226-1923
desormeaupierre@cgocable.ca

SOURCE: Capital Pro-Egaux Inc.